Back to news

Myriad Genetics Expands SRL Partnership in Japan to Support Future Growth

Globe Newswire•17/11/2026•09:05 ET
0

Key Highlights

  • ➤SRL to perform BRACAnalysis laboratory wet work locally in Japan, pending regulatory approval
  • ➤Local testing eliminates sample shipments to Utah, expected to shorten turnaround times
  • ➤Expanded collaboration creates a platform for additional precision medicine and companion diagnostics
  • ➤Myriad intends to pursue further Japanese regulatory approvals and reimbursement

Expert Statements

Vishal Sikri, Executive Vice President, Commercial, Myriad Genetics

“Expanding our collaboration with SRL strengthens our ability to serve patients and health care providers in Japan while creating a platform for long-term profitable growth”

Vishal Sikri, Executive Vice President, Commercial, Myriad Genetics

“Enabling local testing of Myriad’s genetic tests is expected to improve the testing experience and position us to bring additional precision medicine and companion diagnostic offerings to the Japanese market.”

SALT LAKE CITY, Nov. 17, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announces an expansion of its collaboration with SRL, one of the Japan's largest and leading clinical laboratory testing companies, to enable local testing for BRACAnalysis(®) Diagnostic System in Japan, subject to regulatory approval. The collaboration is expected to improve the testing experience for patients and health care providers, while creating a foundation for broader Myriad offerings and long-term growth in Japan.

Local capabilities designed to support growth and future expansion Under the expanded agreement, SRL will perform all laboratory wet work for BRACAnalysis Diagnostic System locally in Japan, while Myriad will continue to provide genetic interpretation services. Because this approach eliminates the need to ship patient samples to Myriad’s central laboratory in Utah for sequencing, it is expected to improve testing efficiency and shorten sample turn-around-time for the clinician and the patient.

Get started

Create a free account to read the full story.

Sign Up

Already have an account? Log in